Does finerenone improve outcomes in patients withheart failure (HF) with mildly reduced or preserved ejection fraction?

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

Over a median of 32 months, finerenone significantly reduced the primary endpoint, with 1,083 events in the finerenone group and 1,283 events in the placebo group (rate ratio 0.84; 95% confidence ...